Artelo Biosciences Regains Nasdaq Compliance, Faces One-Year Panel Monitoring
Artelo Biosciences has regained compliance with Nasdaq Listing Rules 5550(b)(1) and 5620(a) and will be subject to a mandatory panel monitor for one year. The clinical-stage company is advancing its Phase 2 ART27.13 program with encouraging CAReS interim data and progressing potential partnership negotiations.
1. Nasdaq Compliance Restored
Artelo Biosciences received confirmation that it has met Nasdaq Listing Rules 5550(b)(1) and 5620(a) following its reconvened annual meeting and subsequent Form 8-K filings on January 30 and March 30, 2026. This restores its listing status and eliminates immediate delisting threats.
2. One-Year Panel Monitor Imposed
Under Listing Rule 5815(d)(4)(B), the company will operate under a mandatory panel monitor for twelve months to review governance and compliance processes. This oversight aims to ensure ongoing adherence to Nasdaq’s continued listing requirements.
3. Advancing Clinical Pipeline
Artelo highlights encouraging Phase 2 CAReS interim data for ART27.13 in cancer anorexia-cachexia syndrome and progress in an externally funded glaucoma study. The firm’s second clinical asset, ART26.12, is advancing as a non-opioid neuropathic pain candidate, supporting potential partnership discussions and long-term value creation.